

Lynn Yoffee

Medical Device Daily & MDD Perspectives

AHC Media LLC

www.medicaldevicedaily.com <<http://www.medicaldevicedaily.com>> <<http://www.medicaldevicedaily.com>>

3525 Piedmont Road, Building 6, Suite 400

Atlanta, GA 30305

770-361-4789

Emily Shafer

or Jackie Kozloski

215-955-6300

Emily.shafer@jefferson.edu

Description

Researchers Identify Possible Imaging Method to Stratify Breast Cancer Without Biopsy

Source: Thomas Jefferson University

Newswise — Scientists from the Kimmel Cancer Center at Jefferson have discovered a possible way for malignant breast tumors to be identified, without the need for a biopsy. The findings were published online ahead of print in the Journal of Nuclear Medicine.

Current imaging modalities miss up to 30% of breast cancers and cannot distinguish malignant tumors from benign tumors, thus requiring invasive biopsies. Approximately 5.6 million biopsies performed in the United States find only benign lesions. These biopsies cause substantial stress for the patients and have significantly high costs.

“The challenge has been to develop an imaging agent that will target a specific, fingerprint biomarker that visualizes malignant breast lesions early and reliably,” said Mathew Thakur, Ph.D., professor of Radiology at Jefferson Medical College of Thomas Jefferson University and director of Radiopharmaceutical Research and Nuclear Medicine Research.

Dr. Thakur and colleagues studied an agent called ^{64}Cu -TP3805, which is used to evaluate tumors via PET imaging. ^{64}Cu -TP3805 detects breast cancer by finding a biomarker called VPAC1, which is overexpressed as the tumor develops.

The researchers compared the images using that agent with images using the “gold standard” imaging agent, ^{18}F -FDG. They used MMTVneu mice, which are mice that develop breast tumors spontaneously, like humans. The mice first received a PET scan using the ^{18}F -FDG. Then they received a CT scan, and then they received another PET scan using ^{64}Cu -TP3805.

Ten tumors were detected on the mice. Four tumors were detected using both ^{18}F -FDG and ^{64}Cu -TP3805, and four additional tumors were found with ^{64}Cu -TP3805 only. All eight of these tumors overexpressed the VPAC1 oncogene on tumor cells and were malignant by histology. The remaining two tumors were benign and were detected only with ^{18}F -FDG. They did not express the VPAC1 oncogene, and thus were not detected by the ^{64}Cu -TP3805.

“If this ability of ^{64}Cu -TP3805 holds up in humans, then in the future, PET scans with ^{64}Cu -TP3805 will significantly contribute to the management of breast cancer,” Dr. Thakur said.

Other Jefferson researchers involved in the study include Devakumar Devadhas, Ph.D.; Kaijun Zhang, Ph.D.; Richard G. Pestell, M.D., Ph.D.; Chenguang Wang, Ph.D.; Peter McCue, M.D.; and Eric Wickstrom, Ph.D.